Results 201 to 210 of about 3,116,614 (307)

A Clinical Guidance for the Management of Patients With Hepatoid Adenocarcinoma and A Case Series

Cancer Medicine, Volume 15, Issue 2, February 2026.
ABSTRACT Hepatoid adenocarcinoma (HAC) is a rare extrahepatic tumor of non‐germ cell origin that morphologically resembles hepatocellular carcinoma (HCC). HAC has a propensity to metastasize to the liver and therefore may be mistaken for HCC. There is a lack of standardized treatment protocols, and further studies are needed to evaluate the benefit of ...
Christina Liava, Sudhakar Venkatesh, Michael S. Torbenson, Patrick S. Kamath, Moira Hilscher   +4 more
wiley   +1 more source

Corrigendum to: Regorafenib reverses HGF‐induced sorafenib resistance by inhibiting epithelial‐mesenchymal transition in hepatocellular carcinoma

, 2022

openalex   +1 more source

Targeting glucosylceramide synthase increases sorafenib efficacy and evades sorafenib resistance in HCC models

, 2015
Trabajo presentado en el 50th International Liver Congress, celebrado en Viena, Austria, del 22 al 26 de abril de 2015 Peer ...
Stefanovic, Milica, Tutusaus, Anna, Bárcena, Cristina, Martínez-Nieto, Guillermo A., Marí, Montserrat, García-Ruiz, Carmen, Fernández-Checa, José C., Morales, Albert   +7 more
openaire   +1 more source

Impact of Prior Treatment History on Recurrence After Complete Response to Atezolizumab Plus Bevacizumab in Unresectable Hepatocellular Carcinoma

Cancer Medicine, Volume 15, Issue 2, February 2026.
ABSTRACT Aim Integration of locoregional treatments (LRTs) with atezolizumab plus bevacizumab (atezo/bev) has improved treatment outcomes, enabling an increasing number of patients with unresectable hepatocellular carcinoma (HCC) to achieve a complete response (CR). A comprehensive analysis of recurrence following CR may provide insights into prognosis.
Tasuku Nakabori, Masaki Kawabata, Kaori Mukai, Hidenari Hongyo, Noboru Maeda, Makiko Urabe, Yugo Kai, Ryoji Takada, Kenji Ikezawa, Hiroshi Wada, Kunihito Gotoh, Kazuyoshi Ohkawa   +11 more
wiley   +1 more source

Exosomal miR-6126 as a novel therapeutic target for overcoming resistance of anti-cancer effect in hepatocellular carcinoma

BMC Cancer
Background Hepatocellular carcinoma (HCC) stands as the sixth most prevalent cancer globally, presenting a substantial health challenge, particularly due to late-stage diagnoses that limit treatment effectiveness.
Hyemin Hwang, Jimin Kim, Tae-Hun Kim, Yeonju Han, Dayoung Choi, Sua Cho, Seunghwan Kim, Sanghee Park, Taehyun Park, Filippo Piccinini, Won Jong Rhee, Jae-Chul Pyun, Misu Lee   +12 more
doaj   +1 more source

Arginase 2 Promotes Colorectal Cancer Metastasis via PI3K/AKT Pathway Activation and Regulates Tumor Immune Infiltration

Cancer Medicine, Volume 15, Issue 2, February 2026.
ABSTRACT Background Colorectal cancer (CRC) is a leading cause of cancer‐related deaths, with metabolic reprogramming involved in its pathogenesis. Aberrant Arginase 2 (ARG2) expression is linked to malignant progression, but its role in CRC remains unclear. Methods ARG2 expression in CRC and adjacent tissues was analyzed.
Yueyan Zhang, Ning Qu, Jiale Mei, Caixia Mo, Luojuan Wei, Haixian Shen, Shanfei Zhou, Jinmin Hu, Wenqi Luo, Xianwei Mo   +9 more
wiley   +1 more source

Nivolumab plus ipilimumab versus lenvatinib or sorafenib as first‐line treatment for unresectable hepatocellular carcinoma: A cost‐effectiveness analysis

Cancer, Volume 132, Issue 3, 1 February 2026.
Abstract Background Nivolumab plus ipilimumab has shown survival benefits as first‐line treatment for unresectable hepatocellular carcinoma (HCC) but their high cost raises concerns about value. This study assessed the cost‐effectiveness of nivolumab plus ipilimumab compared with lenvatinib or sorafenib from a United States (US) health care payer ...
Jiefeng Luo, Zhengxiong Li, Jun Ge, Sizhen Cai, Xinyi Mo, Wensheng Liu, Chengxia Gui, Qiong Du, Jiyong Liu   +8 more
wiley   +1 more source

Metabolic reprogramming of efferocytosis in the tumour microenvironment: From apoptotic‐cell clearance to therapeutic targeting

Clinical and Translational Medicine, Volume 16, Issue 2, February 2026.
This review systematically deconstructs the pathological efferocytic—metabolic axis in tumours, framing it as a three‐stage, self‐reinforcing cycle: from metabolite‐driven macrophage recruitment, through hijacked surface recognition, to post‐phagocytic metabolic reprogramming that locks in immunosuppression.
Qianlu Yang, Jie Yan, Qianxi Yang
wiley   +1 more source

Elucidation of sorafenib resistance mechanisms in hepatocellular carcinoma

, 2018
75
openaire   +2 more sources

Targeting aerobic glycolysis combats tyrosine kinase inhibitor resistance of hepatocellular carcinoma

International Journal of Cancer, Volume 158, Issue 3, Page 475-487, 1 February 2026.
Abstract Hepatocellular carcinoma (HCC) represents the predominant form of primary liver cancer and is frequently identified at a late stage, necessitating systemic therapy. However, resistance to first‐line tyrosine kinase inhibitor therapies, such as sorafenib and lenvatinib, remains a significant clinical challenge.
Longtao Zhao, Junjie Cheng, Yiming Zheng, Jing Wu, Jia Fan, Haixiang Sun, Chao Gao   +6 more
wiley   +1 more source